Former RayzeBio CEO quickly returns with new biotech; Amgen’s global research leader steps down
Ken Song is back in business.
He left RayzeBio in February after leading the radiopharmaceuticals startup from Series A to IPO in three years, and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
